Assignee
AVANIR PHARMACEUTICALS INC
US·5 granted patents·36 pending applications·151 citations·filing 2005–2023
Top patents by PatentIndex Score
41 records- 0196US7659282B2Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2005·Granted Feb 9, 2010·150 cites·12 claims
- 0285US2023218607A1Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitorAVANIR PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0382US2024124402A1Methods for the synthesis of deuterated dextromethorphanAVANIR PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0480US12291505B2Methods for the synthesis of deuterated dextromethorphanAVANIR PHARMACEUTICALS INC·Filed 2023·Granted May 6, 2025·0 cites·6 claims
- 0578US10730841B2Methods for the synthesis of deuterated dextromethorphanAVANIR PHARMACEUTICALS INC·Filed 2017·Granted Aug 4, 2020·1 cites·2 claims
- 0678US2020276185A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 0776US2020368225A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disordersAVANIR PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 0875US2022105088A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depresson, anxiety, and neurodegenerative disordersAVANIR PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0975US2024082237A1Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementiaAVANIR PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1074US2019054079A1Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitorAVANIR PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1174US2020352933A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementiaAVANIR PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1274US2019060306A1Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitorAVANIR PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1374US2020375981A1Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitorAVANIR PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1473US2014288114A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1573US2019201391A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1673US2021008058A1Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitorAVANIR PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1772US2022105084A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementiaAVANIR PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1871US2014045880A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1971US2017354652A1Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitorAVANIR PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2070US11845731B2Methods for the synthesis of deuterated dextromethorphanAVANIR PHARMACEUTICALS INC·Filed 2020·Granted Dec 19, 2023·0 cites·7 claims
- 2170US2018098984A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2269US2019262332A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementiaAVANIR PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2368US10865187B2Methods for the synthesis of deuterated dextromethorphanAVANIR PHARMACEUTICALS INC·Filed 2020·Granted Dec 15, 2020·0 cites·6 claims
- 2468US2020289499A1Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementiaAVANIR PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2567US2016287576A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2666US2017348301A1Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitorAVANIR PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2765US2019275030A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disordersAVANIR PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2864US2017333423A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementiaAVANIR PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2964US2015209347A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3063US2013072517A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 3160US2016143901A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementiaAVANIR PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3260US2013137714A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disordersAVANIR PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3360US2018008597A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disordersAVANIR PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3457US2022071989A1Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidineAVANIR PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3556US2014315941A1Method of reducing cns and gastrointestinal side affects associated with long-term, dextromethorphan/low-dose quinidine combination therapyAVANIR PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3656US2010137352A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disordersAVANIR PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 3756US2016008353A1Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disordersAVANIR PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3855US2019111047A1Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementiaAVANIR PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3954US2011021552A1Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Depression, Anxiety, and Neurodegenerative DisordersAVANIR PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 4052US2013190346A1Method of reducing cns and gastrointestinal side affects associated with long-term, dextromethorphan/low-dose quinidine combination therapyAVANIR PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4147US2011212987A1Method of reducing cns and gastrointestinal side affects associated with long-term dextromethorphan/low-dose quinidine combination therapyAVANIR PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →